Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
18.4M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
1.32M
-
Shares change
-
+970K
-
Total reported value, excl. options
-
$8.14M
-
Value change
-
+$5.98M
-
Put/Call ratio
-
3.5
-
Number of buys
-
6
-
Number of sells
-
-7
-
Price
-
$6.16
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q3 2024
27 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q3 2024.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.32M shares
of 18.4M outstanding shares and own 7.19% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (987K shares), Wellington Shields Capital Management, LLC (89.2K shares), ADAR1 Capital Management, LLC (64.8K shares), Wellington Shields & Co., LLC (43.1K shares), RENAISSANCE TECHNOLOGIES LLC (41.5K shares), Woodline Partners LP (30.5K shares), CITADEL ADVISORS LLC (22.7K shares), GEODE CAPITAL MANAGEMENT, LLC (19.4K shares), UBS Group AG (14.7K shares), and Royal Bank of Canada (6.9K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.